Eric Olson Biography and Net Worth

Insider of Syros Pharmaceuticals

Eric R. Olson occupies the position of Chief Scientific Officer for Syros Pharmaceuticals, Inc.

He is also on the board of Cystic Fibrosis Foundation and National Brain Tumor Society, Inc.

In the past he occupied the position of Vice President-Research at Vertex Pharmaceuticals, Inc., Research Scientist at The Upjohn Co. and Director-Antibacterials & Molecular Sciences at Warner-Lambert Co.

Dr. Olson received an undergraduate degree from the University of Minnesota and a doctorate from the University of Michigan.

What is Eric R. Olson's net worth?: The estimated net worth of Eric R. Olson is at least $3.33 as of July 17th, 2023. Dr. Olson owns 6,661 shares of Syros Pharmaceuticals stock worth more than $3 as of December 4th. This net worth evaluation does not reflect any other assets that Dr. Olson may own. Learn More about Eric R. Olson's net worth.
How do I contact Eric R. Olson?: The corporate mailing address for Dr. Olson and other Syros Pharmaceuticals executives is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. Syros Pharmaceuticals can also be reached via phone at (617) 744-1340 and via email at [email protected]. Learn More on Eric R. Olson's contact information.
Has Eric R. Olson been buying or selling shares of Syros Pharmaceuticals?: Eric R. Olson has not been actively trading shares of Syros Pharmaceuticals over the course of the past ninety days. Most recently, Eric R. Olson sold 689 shares of the business's stock in a transaction on Monday, July 17th. The shares were sold at an average price of $3.50, for a transaction totalling $2,411.50. Following the completion of the sale, the insider now directly owns 6,661 shares of the company's stock, valued at $23,313.50. Learn More on Eric R. Olson's trading history.

Eric R. Olson Insider Trading History at Syros Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/17/2023	Sell	689	$3.50	$2,411.50	6,661
1/5/2022	Sell	2,208	$3.47	$7,661.76
8/17/2020	Sell	4,963	$13.00	$64,519.00	4,963
7/7/2020	Sell	1,753	$11.72	$20,545.16
8/7/2017	Sell	2,500	$23.59	$58,975.00	2,500
7/25/2017	Sell	12,500	$21.85	$273,125.00	12,500

Eric R. Olson Buying and Selling Activity at Syros Pharmaceuticals

Syros Pharmaceuticals Company Overview

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $0.00

$0.00

50 Day Range

MA: N/A

2 Week Range

Now: $0.00

$0.00

$0.10

Volume

4,381 shs

Average Volume

124,475 shs

Market Capitalization

$13.42 thousand

P/E Ratio

N/A

Dividend Yield